Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an ...

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food ...

Ariceum Therapeutics GmbH’s radiopharmaceutical 225Ac-SSO110 ([225Ac]satoreotide tetraxetran) has been awarded orphan drug designation by the FDA for the treatment of small-cell lung cancer (SCLC).

We recently published a list of 15 Stocks That Took a Nosedive in January. In this article, we are going to take a look at ...

Fintel reports that on February 4, 2025, Wolfe Research initiated coverage of Crinetics Pharmaceuticals (NasdaqGS:CRNX) with ...

We recently published a list of 10 Stocks That Analysts Are Talking About. In this article, we are going to take a look at ...

In November 2024, Novartis partnered with US-based startup Ratio Therapeutics in a $745m deal to develop a somatostatin receptor 2 (SSTR2) radiotherapeutic for cancer treatment. Venture capital ...

Lantheus (LNTH) announced a definitive agreement to acquire Evergreen Theragnostics in an all-cash transaction consisting of an upfront payment ...

The global phase 3 trial enrolled 309 patients with grade 1 or 2 progressive somatostatin receptor (SSTR)-positive neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NETs).

ITM-11, the drug that ITM says succeeded in the Phase 3 neuroendocrine cancer study, contains the isotope lutetium-177, which is packaged together with a compound that targets a protein known as the ...